HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.08
Price-0.66%
-$0.10
1Y
Price
Market Cap
$2.651b
Mid
Price/Earnings 3y Avg5y Avg
5.7x
Premium
Premium
Financials Overview
Key metrics over the past few years-3.1%
EBITDA Margin+3.7%
Net Profit Margin+10.0%
Free Cash Flow MarginRevenue
$630.201m
-24.8%
1y CAGR+30.5%
3y CAGR+36.9%
5y CAGREarnings
$37.729m
-62.6%
1y CAGR-6.0%
3y CAGR-8.8%
5y CAGREPS
$0.22
-62.1%
1y CAGR-1.1%
3y CAGR-1.8%
5y CAGRBook Value
$771.853m
$1.274b
Assets$502.343m
Liabilities$89.820m
DebtDebt to Assets
7.0%
-2.9x
Debt to EBITDAFree Cash Flow
-$17.436m
-109.3%
1y CAGR+4.6%
3y CAGR-39.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company